Outset Medical Inc

Outset Medical Inc(OM)股票分析

$4.100

-0.314 (-7.66%)收盘时

Loading chart…
最高
4.375
开盘
4.210
成交量加权均价
4.12
成交量
163.02K
市值
214.13M
最低
3.890
成交额
671.92K
企业价值/息税折旧摊销前利润(TTM)
-0.82

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.

AI 分析 of Outset Medical Inc (OM)

持有

Outset Medical Inc is currently not a strong buy due to its low current price of $4.02 and a high RSI of 43.084, indicating potential weakness in momentum. The forward P/E ratio is 0, suggesting uncertainty in earnings expectations. Additionally, the stock has lost 68.52% over the past year, which raises concerns about its long-term viability. However, the stock has shown some positive movement with a year-to-date change of +8.65%, indicating potential recovery. The main risk is the upcoming earnings report on November 4, 2026, where an EPS estimate of -0.84 could further impact investor sentiment negatively.

估值指标

Outset Medical Inc(OM)当前预期市盈率为 0.00,5 年平均预期市盈率为 -5.84。

预期市盈率

高估
5 年均值 P/E
-5.84
当前P/E
0.00
高估
-1.00
低估
-10.68

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-4.71
当前EV/EBITDA
-0.82
高估
-0.51
低估
-8.92

预期市销率

合理
5 年均值 P/S
4.35
当前P/S
0.60
高估
9.32
低估
-0.63

Alphio AI 对 OM 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%OM

$19.05

情景价格

基

基准

基准 · 50%OM

$18.74

情景价格

悲

悲观

悲观 · 25%OM

$14.07

情景价格

持有 OM 的大户

K

Konwave AG (Gold 2000)

+ 持有OM

+3.50%

3个月收益率

事件时间线

2026-05-07 (ET)

16:50:00

Company Reports Q1 Revenue of $27.86M, Below Expectations

16:50:00

Outset Reiterates 2026 Revenue Guidance of $125M to $130M

2026-02-11 (ET)

16:10:00

Outset Medical Reports Q4 Revenue of $28.87M

16:10:00

Outset Provides 2026 Revenue Guidance of $125M to $130M

2026-01-27 (ET)

09:10:00

Outset Medical Receives FDA 510(k) Clearance

资讯

OM 常见问题 —— 由 Alphio AI 解答

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Outset Medical Inc is currently not a strong buy due to its low current price of $4.02 and a high RSI of 43.084, indicating potential weakness in momentum. The forward P/E ratio is 0, suggesting uncertainty in earnings expectations. Additionally, the stock has lost 68.52% over the past year, which raises concerns about its long-term viability. However, the stock has shown some positive movement with a year-to-date change of +8.65%, indicating potential recovery. The main risk is the upcoming earnings report on November 4, 2026, where an EPS estimate of -0.84 could further impact investor sentiment negatively.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易